OneSource Specialty Pharma Limited reported strong financial results for the second quarter of FY27. Revenue surged by 37% YoY to ₹5,162 million, driven by new capacity and product launches. EBITDA grew by an impressive 53% YoY to ₹1,633 million, with margins expanding to 31.6%. Adjusted PAT also saw a substantial increase of 109% YoY.
OneSource Announces Strong Q2FY27 Financial Performance
OneSource Specialty Pharma Limited has announced its consolidated financial results for the quarter ended September 30, 2026, showcasing significant year-over-year growth. The company reported a 37% increase in Revenue to ₹5,162 million (or $54.2 million), marking its third consecutive quarter of sequential growth. This performance was attributed to new DDC capacity, strong MSA execution, and multiple product launches across all business segments.
EBITDA and Profitability Surge
The company’s EBITDA reached ₹1,633 million (or $17.2 million), a substantial 53% increase YoY and a 32% increase QoQ. This surge in EBITDA was accompanied by an expansion in EBITDA margins to 31.6%, driven by operating leverage from higher volumes. Adjusted PAT also demonstrated robust growth, increasing by 109% YoY to ₹937 million, with Adjusted EPS at ₹8.2.
Operational Highlights and Future Outlook
The press release highlighted key operational achievements in Q2FY27, including 6 new wins (2 in Biologics), 2 new logos, commercialization of the second cartridge line, and 12 new launches. The company also secured 75+ Active RFPs. Mr. Neeraj Sharma, CEO & MD, expressed optimism about the future, stating, “Q2 delivered strong sequential growth, led by new DDC capacity. With our second cartridge line commercial, H2 will see new launches and a significant ramp-up in commercial volumes.” The company is focused on scaling its DDCs, expanding its Biologics funnel, and growing its Base Business.
Source: BSE
